...
机译:在脾切除,肾切除和FcRn敲除啮齿动物模型中研究选择性AMG 386(一种选择性的血管生成素1/2中和肽体)的清除机制。
Department of Pharmacokinetics &amp Drug Metabolism, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, California, USA;
Department of Pharmacokinetics &amp Drug Metabolism, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, California, USA;
Department of Pharmacokinetics &amp Drug Metabolism, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, California, USA;
Department of Pharmacokinetics &amp Drug Metabolism, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, California, USA;
Department of Pharmacokinetics &amp Drug Metabolism, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, California, USA;
Department of Pharmacokinetics &amp Drug Metabolism, Amgen Inc., One Amgen Center Drive, Mailstop 28-3-B, Thousand Oaks, California, USA;
AMG 386; clearance mechanism; neonatal Fc receptor; nephrectomy; peptibody;
机译:在脾切除,肾切除和FcRn基因敲除啮齿动物模型中研究选择性AMG 386(一种选择性血管生成素中和肽体)的清除机制。
机译:AMG-386,一种选择性的血管生成素-1 / -2-中和肽体,可潜在治疗癌症。
机译:AMG-386,一种选择性血管发成素-1 / -2中和癫痫,用于癌症的潜在治疗。
机译:在脾切除肾切除和FcRn敲除啮齿动物模型中研究选择性AMG 386(一种选择性血管生成素1/2中和肽体)的清除机制。
机译:在脾切除,肾切除和FcRn敲除啮齿动物模型中研究选择性AMG 386(一种选择性的血管生成素1/2中和肽体)的清除机制。